MX2008006696A - F,g,h,i and k crystal forms of imatinib mesylate - Google Patents

Abstract

The invention relates to the F-crystalform, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)- N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.

Description

FORMS OF CRYSTAL F. G. H. I. and K OF THE M ISILATO DE IMATI NI B The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4- (4-methyl-piperazin-1-ylmethyl) -N- [4-methyl-3- (4- (pyridin-3- il) -pyrimidin-2-ylamino) -phenyl] -benzamide (the compound of Formula I, see below), to certain processes for their preparation, to pharmaceutical compositions containing these crystal forms, and to their use in methods of diagnosis, or preferably for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods, or preferably for the therapeutic treatment of animals of warm blood, especially human beings. BACKGROUND OF THE INVENTION The preparation of 4- (4-methyl-piperazin-1-ylmethyl) -N- [4-methyl-3- (4- (pyridin-3-yl) -pyrimidin-2-ylamino) - phenyl] -benzamide, also known as I matinib, and its use, especially as an antitumor agent, are described in Example 21 of European Patent No. EP-A-0,564,409, which was published on October 6, 1 993, and in equivalent applications in numerous other countries. The compound is exemplified in these publications only in free form (and not as a salt). 4- (4-Methyl-piperazin-1-methylmethyl) -N- [4-methyl-3- (4- (pyridin-3-yl) -pyrimidin-2-ylamino) -phenyl] -benzamide mesylate, also known as Imatinib mesylate or STI571, the alpha and beta crystal forms thereof, as well as their pharmaceutical use, are described in U.S. Patent Number US 6,894,051. Imatinib mesylate is the active ingredient in the drug Gleevec® (Glivec®), which is an approved medication for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Another polymorph of Imatinib mesylate, the so-called H1-form, is described in International Publication Number WO2004 / 106326. It has now been found, in a surprising manner, that, under certain conditions, new crystal forms of the methanesulfonate salt can be found, which are hereinafter described as F-crystal form, G-crystal form, form of crystal-H, form of crystal-l, and form of crystal-K, and whose forms have utilities and convenient properties. Detailed Description of the Invention The invention is described in greater detail in the following, with the help of the drawings and other auxiliaries. The invention relates in particular to essentially pure crystal forms, preferably those which are hereinafter referred to as the F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and K-crystal form of the methanesulfonic acid addition salt of the Imatinib of Formula I: DESCRIPTION OF THE DRAWINGS The F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by lines in the X-ray diffraction pattern observed at a 2-theta refractive angle of 8.4 °. and 8.6 °. Figure 1 shows the X-ray diffraction diagram of the F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I. In the X-ray diagram, the 2-theta refractive angle is plotted on the horizontal axis (x-axis), and the relative line intensity (peak intensity corrected by the background) on the vertical axis (y-axis) . X-ray powder diffraction patterns are measured on a Bruker D8 GADDS Discover Diffractometer Diffractometer, with the Cu Ka radiation source (Ka1 radiation, wavelength? = 1 .54060 Anglestroms). The optical density of the lines on the film is proportional to the intensity of the light. The movie is scanned using a line scanner. The strongest line in the X-ray diffraction diagram is observed at a 2-theta refractive angle of 20.9 °. More broadly, the F-crystal shape is characterized by refractions at 2-theta refractive angles of 8.4 °, 8.6 °, 1 3.3 °, 1 6.2 °, 1 6.8 °, 1 7.1 °, 1 9.5 °, 20.9 °, 23.6 °, and 24. 5. In the essentially pure material of the F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, the lines can be observed at the refractive angles 2-teta of 8.4 °, 8.6 °, 10.4 ° , 13.3 °, 14.7 °, 16.2 °, 16.8 °, 17.1 °, 19.5 °, 20.9 °, 22.2 °, 23.1 °, 23.6 °, 24.5 °, 25.1 °, 26.0 °, 26.9 °, 28. 5 °, 29.1 °, and 30.3 °. The crystal-G form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by a line on the X-ray diffraction pattern, observed at a 2-theta refractive angle of 10.5 °, together with the absence of lines between a 2-theta refraction angle of 4 ° and 8 °. Figure 2 shows the X-ray diffraction diagram of the crystal-G form of the methanesulfonic acid addition salt of a compound of Formula I. In the X-ray diagram, the refractive angle 2-teta it is plotted on the horizontal axis (x-axis), and the relative line intensity (peak intensity corrected by the background) on the vertical axis (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 GADDS Discover Diffractometer Diffractometer, with the Cu Ka radiation source (Ka1 radiation, wavelength? = 1.54060 Anglestroms). The optical density of the lines on the film is proportional to the intensity of the light. The movie is scanned using a line scanner. In the X-ray diffraction diagram of the crystal-G shape, the lines are observed at a 2-theta refractive angle of 10.5 °, 18.1 °, and 18.7 °. More broadly, the crystal-G form is characterized by refractions in refractive angles 2-theta of 10.5 °, 15.0 °, 17.2 °, 18.1 °, 18.7 °, 19.2 °, 21.1 °, and 21.3 °. In the essentially pure material of the crystal-G form of the methanesulfonic acid addition salt of a compound of Formula I, the lines can be observed at the refractive angles 2-teta of 10.5 °, 12.9 °, 13.9 ° , 14.1 °, 15.0 °, 16.6 °, 17.2 °, 17.5 °, 18.1 °, 18.7 °, 19.2 °, 19.8 °, 20.6 °, 21.1 °, 21.3 °, 21.7 °, 22.1 °, 22.8 °, 23.9 °, 24.3 °, 25.1 °, and 28.6 °. The H-crystal form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by a line on the X-ray diffraction pattern, observed at a 2-theta refractive angle of 32.9 °. Figure 3 shows the X-ray diffraction diagram of the H-crystal form of the methanesulfonic acid addition salt of a compound of Formula I. In the X-ray diagram, the refractive angle 2-teta is plotted on the horizontal axis (x-axis), and the relative line intensity (peak intensity corrected by the background) on the vertical axis (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 GADDS Discover Diffractometer Diffractometer, with the Cu Ka radiation source (Ka1 radiation, wavelength? = 1.54060 Anglestroms). The optical density of the lines on the film is proportional to the intensity of the light. The movie is scanned using a line scanner. In the X-ray diffraction diagram, the H-crystal shape is dominated by a line at a 2-theta refractive angle of 25.1 °. More broadly, the H-crystal form is characterized by refractions in 2-theta refractive angles of 10.5 °, 22.8 °, 25.1 °, and 32.9 °. In the essentially pure material of the H-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, the lines can be observed at the refractive angles 2-teta of 10.5 °, 13.8 °, 15.7 ° , 18.1 °, 21.0 °, 22.8 °, 24.3 °, 25.1 °, 26.3 °, 29.7 °, and 32.9 °. The crystal-l form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by a line on the X-ray diffraction pattern, observed at a refractive angle 2-teta of 12.9 °, together with the absence of lines at a 2-theta refractive angle below 9 ° and above 29 °. Figure 4 shows the X-ray diffraction diagram of the crystal-l form of the methanesulfonic acid addition salt of a compound of Formula I. In the X-ray diagram, the 2-theta refraction angle is plotted on the horizontal axis (x-axis), and the relative line intensity (peak intensity corrected by the background) on the vertical axis (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 GADDS Discover Diffractometer Diffractometer, with the Cu Ka radiation source (Ka1 radiation, wavelength? = 1.54060 Anglestroms). The optical density of the lines on the film is proportional to the intensity of the light. The movie is scanned using a line scanner. In the X-ray diffraction diagram of the crystal-l shape, the lines are observed at a 2-theta refractive angle of 12.9 °, 17.1 °, 20.9 °, 23.9 °, and 24.3 °. More widely, the crystal-l form is characterized by refractions in refractive angles 2-theta of 12.9 °, 14.1 °, 17.1 °, 18.0 °, 18.7 °, 19.1 °, 19.8 °, 20.9 °, 23.9 °, 24.3 °, and 25.2 °. In the essentially pure material of the crystal-1 form of the methanesulfonic acid addition salt of a compound of Formula I, the lines can be observed at the refractive angles 2-teta of 9.6 °, 12.9 °, 14.1 ° , 15.2 °, 15.6 °, 17.1 °, 18.0 °, 18.7 °, 19.1 °, 19.8 °, 20.9 °, 23.4 °, 23.9 °, 24.3 °, 25.2 °, and 28.4 °. The K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by a line on the X-ray diffraction pattern, observed at a 2-theta refractive angle of 37.9 °. Figure 5 shows the X-ray diffraction diagram of the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I. In the X-ray diagram, the refractive angle 2-teta it is plotted on the horizontal axis (x-axis), and the relative line intensity (peak intensity corrected by the background) on the vertical axis (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 GADDS Discover Diffractometer Diffractometer, with the Cu Ka radiation source (Ka1 radiation, wavelength? = 1.54060 Anglestroms). The optical density of the lines on the film is proportional to the intensity of the light. The movie is scanned using a line scanner. In the X-ray diffraction diagram, the K-crystal shape is further characterized by a line at a 2-theta refractive angle of 21.0 °. More broadly, the K-crystal shape is characterized by refractions at 2-theta refractive angles of 12.1 °, 14.1 °, 18.2 °, 18.4 °, 21.0 °, 23.4 °, and 28.4 °. In the essentially pure material of the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, the lines can be observed at the 2-theta refractive angles of 12.1 °, 12.9 °, 13.6 ° , 14.1 °, 15.2 °, 17.2 °, 18.2 °, 18.4 °, 19.8 °, 21.0 °, 22.4 °, 23.4 °, 24.3 °, 25.2 °, 28.4 °, 29.2 °, and 37.9 °. The term "essentially pure" is understood in the context of the present invention to mean in particular that at least 90, preferably at least 95, and more preferably at least 99 weight percent of the crystals of a salt of acid addition of Formula I, are present in the specified crystal form according to the invention. In the context with the statement that the F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I exhibits an X-ray diffraction pattern essentially as in Figure 1, the term "essentially" means that at least the major lines of the diagram illustrated in Figure 1 must be present, ie those that have a relative line intensity greater than 20 percent, especially greater than 30 percent, compared to the most intense line of the diagram. Alternatively, the F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I is characterized by a DSC curve that exhibits a fusion event to 95 ° C, followed by an exothermic recrystallization and a second melt at approximately 223 ° C. In a preferred embodiment, the methanesulfonic acid addition salt of a compound of the essentially pure Formula I, in the crystal-F form, shows the X-ray diffraction pattern indicated in Figure 1. It is also given a high Preference for the F-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, which shows an X-ray diffraction pattern of the type shown in Figure 1, wherein the relative peak intensities of each peak do not deviate by more than 10 percent of the relative peak intensities in the diagram shown in Figure 1, especially an X-ray diffraction pattern identical to that shown in Figure 1. In the context with the statement that the crystal-G form of the methanesulfonic acid addition salt of a compound of Formula I exhibits an X-ray diffraction pattern essentially as in Figure 2, the term "essentially" means that at least the major lines of the diagram illustrated in Figure 2 must be present, ie those that have a relative line intensity greater than 20 percent, especially greater than 30 percent, comparing with the most intense line of the diagram. In a preferred embodiment, the methanesulfonic acid addition salt of a compound of the essentially pure Formula I in the crystal-G form, it shows the X-ray diffraction diagram indicated in Figure 2. There is also a high preference for the G-crystal form of the methanesulfonic acid addition salt of a compound of the Formula I, which shows an X-ray diffraction diagram of the type shown in Figure 2, where the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 2, especially an X-ray diffraction pattern identical to that shown in Figure 2. In the context with the statement that the H-crystal form of the methanesulfonic acid addition salt of a compound of Formula I exhibits an X-ray diffraction diagram essentially as in Figure 3, the term "essentially" means that at least the major lines of the diagram illustrated in Figure 3, that is, those having an intensity of Relative line greater than 20 percent, especially greater than 30 percent, compared to the most intense line in the diagram. In another preferred embodiment, the methanesulfonic acid addition salt of an essentially pure compound of Formula I, in the H-crystal form, shows the X-ray diffraction pattern indicated in Figure 3. It is also given a high preference for the H-crystal form of the methanesulfonic acid addition salt of a compound of the Formula I, an X-ray diffraction diagram of the type shown in Figure 3 is shown, wherein the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 3, especially an X-ray diffraction diagram identical to that shown in Figure 3. In the context with the statement that the crystal-l form of the methanesulfonic acid addition salt of a compound of Formula I exhibits an X-ray diffraction diagram essentially as in Figure 4, the term "essentially" means that at least the major lines of the diagram illustrated in Figure 4, ie, those having a line intensity, must be present. relative to more than 20 percent, especially greater than 30 percent, compared to the most intense line in the diagram. In a further preferred embodiment, the methanesulfonic acid addition salt of a compound of essentially pure Formula I, in the crystal-l form, shows the X-ray diffraction pattern indicated in Figure 4. There is also a high preference for the crystal-l form of the methanesulfonic acid addition salt of a compound of Formula I, which shows an X-ray diffraction pattern of the type shown in Figure 4, wherein the relative peak intensities of each peak does not deviate by more than 10 percent of the relative peak intensities in the diagram shown in Figure 4, especially an X-ray diffraction pattern identical to that shown in Figure 4. In the context with the statement that the K-crystal form of the methanesulfonic acid addition salt of a compound of the Formula exhibits a diagram of X-ray diffraction essentially as in Figure 5, the term "essentially" means that at least the major lines of the diagram illustrated in Figure 5, that is, those having a relative line strength greater than 20, must be present. percent, especially greater than 30 percent, compared to the most intense line in the diagram. In another preferred embodiment, the methanesulfonic acid addition salt of an essentially pure compound of Formula I, in the crystal-K form, shows the X-ray diffraction pattern indicated in Figure 5. It also gives a high Preference for the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, which shows an X-ray diffraction pattern of the type shown in Figure 5, wherein the relative peak intensities of each peak do not deviate by more than 10 percent of the relative peak intensities in the diagram shown in Figure 5, especially an X-ray diffraction pattern identical to that shown in Figure 5. The invention also expressly refers to the forms of the methanesulfonic acid addition salt of a compound of Formula I, wherein the crystals of the form of crystal-F, of the crystal-G form, of the crystal-H form, of the crystal-l form, and of the K-crystal form, together with other crystal forms, in particular the crystal-form, crystal-ß form, and / or amorphous form of I matinib mesylate. However, the essentially pure form in the form of crystal-F, the crystal-G form, the crystal-H form, the crystal-l form, or the K-crystal form is preferred. A particularly special preference is given for the crystal forms of the methanesulfonic acid addition salt of a compound of Formula I, which can be obtained as described in the Examples. A utility of the F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and the K-crystal form of the acid addition salt Methanesulfonic acid of a compound of Formula I is the use as an intermediate for the preparation of a crystal form other than the methanesulfonic acid addition salt of a compound of Formula I, especially the crystal-β form. The crystal-ß form (preferably essentially pure) can be obtained by: a) Digesting the crystal-F form, the crystal-G form, the H-crystal form, the crystal-l form, or the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, with a suitable polar solvent, especially an alcohol, more especially methanol, or also a ketone (especially in a mixture with water, water / acetone example), typically acetone, an N, N-di-lower alkyl-lower alkane-carboxamide, typically NN-dimethyl-formamide or -acetamide, or a hydrophilic ether, typically dioxane, preferably in the presence of some water, or mixtures thereof , in suspension at a suitable temperature, preferably at a temperature bet 20 ° C and 50 ° C, for example at about 25 ° C, or b) Dissolve the crystal-F form, the crystal-G form, the of crystal-H, the crystal-l form, or the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, with a suitable polar solvent, such as especially an alcohol, typically methanol or ethanol, a ketone (especially in a mixture with water, for example water / acetone), typically acetone, an N, N-di-lower alkyl-lower alkane-carboxamide, typically NN-dimethyl-formamide or -acetamide, or a hydrophilic ether, typically dioxane, or mixtures thereof, preferably in the presence of something d water, at a suitable temperature, especially after heating the solvent, or with heating during the dissolution process, in both cases preferably from 25 ° C to the reflux temperature of the reaction mixture, and then the crystallization by adding a small amount of the crystal-ß form as seed crystal at a suitable temperature, for example bet 0 ° C and 70 ° C, preferably bet 20 ° C and 70 ° C. One of the advantages of having access to different crystal forms of the compound of Formula I is the fact that the Different forms of crystal are susceptible to the incorporation of d istintas im purities after crystallization, is to say, a imputed imputed in the form of crystal-ß is not necessarily also incorporated in the form of crystal-F , the crystal-G form, the crystal-H form, the crystal-l form, or the K-crystal form. In other words, the preparation of consecutively different crystal forms of the same material increases the pore of the finally obtained substance. In addition, the different forms of glass exhibit different physical properties, such as melting points, hygroscopicities, solubilities, flow properties, or thermodynamic stabilities, and consequently, the different forms of glass allow to make the choice of the most suitable form for certain use or appearance, for example the use as an intermediary in the process of making a drug, or in different forms of administration such as tablets, capsules, or nuggets, or solutions. The F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I , possess valuable pharmacological properties, and can be used, for example, as an antitumor agent or as an agent to treat restenosis. The present invention relates in particular to the F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and the K-crystal form of the acid addition salt. methanesulfonic acid of a compound of Formula I, in the treatment of one of the diseases mentioned herein, or in the preparation of a pharmacological agent for the treatment thereof. The antiproliferative activity, in particular antitumor, of the methanesulfonic acid addition salt of a compound of the formula I in vivo is described, for example, for the treatment of abl-dependent tumors, in Nature Med.2, 561-6 ( nineteen ninety six). The invention also relates to a method for the treatment of warm-blooded animals suffering from these diseases, especially leukemia, wherein an amount of the crystal-F form, the crystal-G form, the H-crystal form, the crystal-l form, or the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I which is effective against the disease concerned, especially an amount with antiproliferative efficacy , to warm-blooded animals that need this treatment. Moreover, the invention relates to the use of the F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and the K-crystal form of the addition salt. of methanesulfonic acid of a compound of Formula I, for the preparation of pharmaceutical compositions for use in the treatment of the human or animal body, in particular for the treatment of tumors, such as gliomas or prostate tumors. In preferred embodiments, the present invention relates to the use of the F-crystal form, the crystal-G form, the form of H-crystal, the crystal-1 form, and the K-crystal form of the methanesulfonic acid addition salt of a compound of Formula I, in the treatment of one of the disorders listed below: 1. Metastatic GIST inoperable, 2. Advanced chronic myeloid leukemia, 3. Newly diagnosed chronic myeloid leukemia, 4. Pediatric Philadelphia chromosome-positive chronic myeloid leukemia, 5. Philadelphia-positive acute lymphocytic leukemia (ALL), 6. Glioblastoma multiforme, preferably in combination with hydroxy urea, 7. Dermatofibrosarcoma protuberans (DFSP), 8. Hyper-eosinophilic syndrome (HES), and 9. Chronic myelomonocytic leukemia (CMML). Depending on the species, age, individual condition, mode of administration, and the clinical picture in question, effective doses are administered, for example daily doses of about 50 to 2,500 milligrams, preferably 100 to 1,000 milligrams, especially of 250 to 800 milligrams of Imatinib having the form of crystal-F, the crystal-G form, the crystal-H form, the crystal-l form, or the K-crystal form, to warm-blooded animals of a body weight of approximately 70 kilograms. Preferably, daily dosages of 400 milligrams or 600 are orally administered milligrams once a day, preferably together with a food and a large glass of water (approximately 200 milliliters). Preferably daily dosages of 800 milligrams are administered in the form of dosages of 400 milligrams twice a day together with the feed. The F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, or the K-crystal form described herein, can be used to prepare stable pharmaceutical dosage forms. . Accordingly, the invention also relates to pharmaceutical preparations containing an amount, especially an effective amount for the prevention or treatment of one of the diseases mentioned herein, of the methanesulfonic acid addition salt of a compound of the invention. Formula I in the form of crystal-F, the crystal-G form, the crystal-H form, the crystal-l form, or in the K-crystal form, together with pharmaceutically acceptable carriers that are suitable for administration topical, enteral, for example oral or rectal, or parenteral, and may be inorganic or organic and solid or liquid. Especially, for oral administration, tablets or gelatin capsules containing the active substance are used together with diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycerin, and / or lubricants, eg silica, talc, stearic acid, or salts thereof, typically magnesium or calcium stearate, and / or polyethylene glycol. The tablets in the same manner may contain binders, for example magnesium silicate and aluminum, starches, typically corn starch or rice starch, gelatin, methyl cellulose, sodium carboxy methyl cellulose, and / or polyvinyl pyrrolidone, and if desired, disintegrants, eg, starches, agar, alginic acid or a salt thereof, typically sodium alginate, and / or effervescent mixtures, or adsorbents, coloring agents, flavorings, and sweetening agents. The pharmacologically active compounds of the present invention can be further used in the form of preparations for parenteral administration or solutions for infusion. These solutions are preferably isotonic aqueous solutions or suspensions, and these are possibly prepared before use, for example in the case of lyophilized preparations containing the active substance either alone or together with a carrier, for example mannitol. The pharmaceutical substances can be sterilized and / or contain excipients, for example preservatives, stabilizers, wetting agents and / or emulsifiers, solubilizers, salts for regulation of the osmotic pressure, and / or pH regulators. The present pharmaceutical preparations which, if desired, may contain additional pharmacologically active substances, are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving, or lyophilizing processes, and may contain about 1 percent to 100 percent, especially from about 1 percent to about 20 percent of the substance or active substances. In a preferred embodiment, the tablet or capsule contains 50 milligrams or 100 milligrams of the addition salt of methanesulfonic acid of a compound of Formula I in the form of crystal-F, in the form of crystal-G, in the form of crystal-H, in the form of crystal-1, or in the K-crystal form, optionally with pharmaceutically acceptable carriers. In one embodiment, the capsule is a hard gelatin capsule containing a mixture of dry powder. The capsule shell preferably contains gelatin and titanium dioxide, as well as red iron oxide. The weight ratio of the capsule filling to the capsule shell is preferably between approximately 100: 5 and 100: 50, more preferably between 100: 30 and 100: 40. In another embodiment, a film-coated tablet comprising 100 milligrams, 400 milligrams, or 800 milligrams of drug substance, together with inactive excipients selected from colloidal anhydrous silica, polyvinyl pyrrolidone, magnesium stearate, and microcrystalline cellulose is used. . The following Examples illustrate the invention without limiting its scope. Temperatures are given in degrees Celsius (° C). EXAMPLES Example 1: Preparation of the crystalline form F of the mesylate of Imatinib using benzyl alcohol First, approximately 500 milligrams of Imatinib mesylate are dissolved in approximately 100 milliliters of water. Approximately 50 microliters of the supply solution in a CRISSY block of 96 wells, to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with 250 microliters of benzyl alcohol. The suspension or solution is stirred using the high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. Example 2: Preparation of the crystalline form F of Imatinib mesylate using a mixture of benzyl alcohol and ethyl acetate First, approximately 500 milligrams of Imatinib mesylate is dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution are dosed manually into a CRISSY block of 96 wells, to have an amount total drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with a mixture of 222 microliters of benzyl alcohol and 28 microliters of ethyl acetate. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C for about 2 hours. Then the solution is allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. Example 3: Preparation of the crystalline form F of Imatinib mesylate using a mixture of benzyl alcohol v 1, 4-dioxane. 3-pentanone, or di-isopropyl ether First, approximately 500 milligrams of Imatinib mesylate is dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution is manually dosed in a 96-well CRISSY block to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with a mixture of 214 microliters of benzyl alcohol and 36 microliters of 1,4-dioxane, 3-pentanone, or di-isopropyl ether. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. The crystals obtained from the mixture consist of benzyl alcohol / di-isopropyl ether. A DSS curve (recorded using a Perkin Elmer DSC-7 instrument with a heating rate of 10 ° K / minute and a sampling mass of approximately 0.7 milligrams) shows a melting event at 95 ° C, followed by an exothermic recrystallization and a second melt at about 223 ° C. Example 4: Preparation of the crystalline form F of Imatinib mesylate using a mixture of benzyl alcohol and acetonitrile or dimethylformamide First about 500 milligrams of Imatinib mesylate are dissolved in approximately 100 milliliters of water. Approximately 50 microliters of the supply solution in a CRISSY block of 96 wells, to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with a mixture of 200 microliters of benzyl alcohol and 50 microliters of acetonitrile or dimethylformamide. The suspension or solution is stirred using the high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. Example 5: Tablets with Imatinib mesylate. crystal form-F Tablets containing 100 milligrams of the active substance mentioned in the title are normally prepared in the following composition: Composition Active ingredient 100 mg Crystalline lactose 240 mg Avicel 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg 447 mg Preparation: The active substance is mixed with the vehicle materials, and compressed in a tablet-forming machine (Korsch EKO, diameter of the 10-millimeter drill). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA).

PVPPXL is cross-linked polyvinyl-polypyrrolidone (BSAF, Germany). Aerosil is silicon dioxide (Degussa, Germany). Example 6: Capsules with Imatinib mesylate, F-crystal form Capsules containing 100 milligrams of the compound mentioned in the title as active substance are normally prepared in the following composition: Composition Active ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1. Example 7: Preparation of the crystalline form G of Imatinib mesylate using a mixture of 3-pentanone v cyclohexane First, about 500 milligrams of imatinib mesylate are dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution is manually dosed in a 96-well CRISSY block to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with a mixture of 125 microliters of 3-pentanone and 125 microliters of cyclohexane. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate from 45 ° C to 55 ° C under a stream of nitrogen. Example 8: Tablets with Imatinib mesylate, form of crystal-G Tablets containing 100 milligrams of the active substance mentioned in the title, are normally prepared in the following composition: Composition Active ingredient 100 mg Crystalline lactose 240 mg Avicel 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg 447 mg Preparation: The active substance is mixed with the vehicle materials, and compressed in a tablet-forming machine (Korsch EKO, diameter of the 10-millimeter drill). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is cross-linked polyvinyl-polypyrrolidone (BSAF, Germany). Aerosil is silicon dioxide (Degussa, Germany). Example 9: Capsules with Imatinib mesylate. Glass shape-G Capsules containing 100 milligrams of the compound mentioned in the title as active substance are usually prepared in the following composition: Composition Active ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg Capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1. Example 10: Preparation of the crystalline form-H of the mesylate of Imatinib using a mixture of 3-pentanone and N.N-dimethylformamide First about 500 milligrams of Imatinib mesylate are dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution is manually dosed in a 96-well CRISSY block to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended with a mixture of 125 microliters of 3-pentanone and 125 microliters of N, N-dimethylformamide. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C during approximately 2 hours. The solution is then allowed to evaporate from 45 ° C to 55 ° C under a stream of nitrogen. Example 11: Tablets with Imatinib mesylate, H-crystal form Tablets containing 100 milligrams of the active substance mentioned in the title are normally prepared in the following composition. Composition Active ingredient 100 mg Crystalline lactose 240 mg Avicel 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg 447 mg Preparation: The active substance is mixed with the carrier materials, and compressed in a tablet-forming machine (Korsch EKO , diameter of the drill of 10 mm). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is cross-linked polyvinyl-polypyrrolidone (BSAF, Germany). Aerosil is silicon dioxide (Degussa, Germany). Example 12: Capsules with Imatinib mesylate, H-crystal form Capsules containing 100 milligrams of the compound mentioned in the title as active substance, are usually prepared in the following composition: Composition Active ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1. Example 13: Preparation of the crystalline form- the mesylate of Imatinib using a mixture of ethyl acetate and diethyl ether First about 500 milligrams of imatinib mesylate are dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution is manually dosed in a 96-well CRISSY block to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended in a mixture of 125 microliters of ethyl acetate and 125 microliters of diethyl ether. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. Example 14: Tablets with Imatinib mesylate, crystal-l form Tablets containing 100 milligrams of the substance active mentioned in the title, are usually prepared in the following composition: Composition Active ingredient 100 mg Crystalline lactose 240 mg Avicel 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg 447 mg Preparation: The active substance is mixed with the materials of vehicle, and compressed into a tablet-forming machine (Korsch EKO, diameter of the 10-millimeter drill). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is cross-linked polyvinyl-polypyrrolidone (BSAF, Germany). Aerosil is silicon dioxide (Degussa, Germany). Example 15: Capsules with Imatinib mesylate, crystal-l form Capsules containing 100 milligrams of the compound mentioned in the title as active substance are usually prepared in the following composition: Composition Active ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1. Example 16: Preparation of the crystalline form K of the mesylate of Imatinib using a mixture of ethyl acetate and N.N-dimethylformamide First about 500 milligrams of Imatinib mesylate are dissolved in approximately 100 milliliters of water. About 50 microliters of the supply solution is manually dosed in a 96-well CRISSY block to have a total amount of drug substance of 5 milligrams per well. The solution is flooded with nitrogen at room temperature to dry the solution. The dried precipitate is resuspended in a mixture of 125 microliters of ethyl 3-acetate and 125 microliters of N.N-dimethylformamide. The suspension or solution is stirred using a high speed vortex at about 45-55 ° C for about 2 hours. The solution is then allowed to evaporate at 45 ° C to 55 ° C under a stream of nitrogen. Example 17: Tablets with Imatinib mesylate, K-crystal form Tablets containing 100 milligrams of the active substance mentioned in the title are normally prepared in the following composition: Active ingredient 100 mg Crystalline lactose 240 mg Avicar 80 mg PVPPXL 20 mg Aerosil 2 mg Magnesium stearate 5 mg 447 mg Preparation: The active substance is mixed with the carrier materials, and compressed in a tablet-forming machine (Korsch EKO, diameter of the 10 mm drilling machine). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is cross-linked polyvinyl-polypyrrolidone (BSAF, Germany). Aerosil is silicon dioxide (Degussa, Germany). Example 18: Capsules with Imatinib mesylate, K-crystal form Capsules containing 100 milligrams of the compound mentioned in the title as active substance, are normally prepared in the following composition: Active ingredient 100 mg Avicel 200 mg PVPPXL 15 mg Aerosil 2 mg Magnesium stearate 1.5 mg 318.5 mg The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Claims (73)

1. REVIVALATION IS 1 . The crystalline-F form of the methanesulfonic acid addition salt of a compound of Formula I: which shows the X-ray diffraction peaks at a 2-theta refractive angle of 8.4 ° and 8.6 °, and where the strongest line in the X-ray diffraction pattern is observed at a refractive angle 2 -20.9 ° tea.
2. 2. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to claim 1, which shows, in an X-ray diffraction diagram, lines at the following refractive angles. tit: 8.4 °, 8.6 °, 1 3.3 °, 1 6.2 °, 16.8 °, 1 7.1 °, 1 9.5 °, 20.9 °, 23.6 °, and 24.5 °.
3. 3. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 1 or 2, which is present in an essentially pure form.
4. 4. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: which shows an X-ray diffraction diagram of the type shown in Figure 1, wherein the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in the Figural.
5. 5. A composition containing the methanesulfonic acid addition salt of a compound of Formula I: which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 1 or 2.
6. 6. The composition according to claim 5, which additionally comprises at least one different form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the form of crystal-a, the crystal-ß form, and the crystal-H form 1.
7. 7. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
8. 8. The pharmaceutical composition according to claim 7, which additionally comprises at least one other form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the crystal form. a, the crystal-ß form, and the crystal-H form 1.
9. 9. The pharmaceutical composition according to claim 7 or 8, which comprises between 50 milligrams and 800 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of the claims. 1 or 2.
10. 1 0. The pharmaceutical composition according to any of claims 7 to 9, which is a capsule containing a mixture of dry powder comprising between 50 milligrams and 200 milligrams of a crystalline form of the salt. of addition of methanesulfonic acid of a compound of Formula I according to any of claims 1 or 2.
11. 1 1. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: characterized by a DSC curve showing a melting event at 95 ° C, followed by an exothermic recrystallization and a second melting at approximately 223 ° C.
12. 12. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of Formula I, according to claim 11, and optionally a pharmaceutically acceptable carrier.
13. 13. The crystalline-G form of the methanesulfonic acid addition salt of a compound of Formula I:
14. 14. The crystalline form according to claim 13, which shows an X-ray diffraction peak at a 2-theta refractive angle of 10.5 ° in the absence of lines between a 2-theta refractive angle of 4 ° and 8 ° .
15. 15. The crystalline form according to claim 13, which is characterized by X-ray diffraction peaks at a 2-theta refractive angle of 10.5 °, 18.1 °, and 18.7 °.
16. 16. The crystalline form of the methanesulfonic acid addition salt of a compound of Formula I according to claim 13 or 14, which shows, in an X-ray diffraction pattern, lines at the following refractive angles 2-theta: 10.5 °, 15.0 °, 17.2 °, 18.1 °, 18.7 °, 19.2 °, 21.1 °, and 21.3 °.
17. 17. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 13 to 16, which is present in an essentially pure form.
18. 18. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: which shows an X-ray diffraction diagram of the type shown in Figure 2, where the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 2 19.
19. A composition containing the methanesulfonic acid addition salt of a compound of Formula I: which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 13 to 16.
20. The composition according to claim 19, which additionally comprises at least one a different form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the crystal-form, the crystal-form, and the crystal form-H1.
21. 21. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 13 to 16, optionally together with a pharmaceutically acceptable carrier.
22. 22. The pharmaceutical composition according to claim 21, which additionally comprises at least one other form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the crystal form. a, the crystal-ß form, and the crystal-H1 form.
23. 23. The pharmaceutical composition according to claim 21 or 22, which comprises between 50 milligrams and 800 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of Formula I according to any of claims 13 to 16.
24. The pharmaceutical composition according to any of claims 21 to 23, which is a capsule containing a dry powder mixture comprising between 50 milligrams and 200 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 13 to 16.
25. 25. The crystalline form H of the methanesulfonic acid addition salt of a compound of Formula I:
26. 26. The crystalline form according to claim 25, which shows, in X-ray diffraction, a peak at a refractive angle 2-teta of 32.9 °.
27. 27. The crystalline form according to claim 25, which is characterized by an X-ray diffraction peak at a 2-theta refractive angle of 25.1 °.
28. 28. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 25 to 27, which shows in a X-ray diffraction diagram, lines at the following 2-theta refractive angles: 10.5 °, 22.8 °, 25.1 °, and 32.9 °.
29. 29. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 25 to 28, which is present in an essentially pure form.
30. 30. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: which shows an X-ray diffraction pattern of the type shown in Figure 3, where the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 3.
31. 31. A composition containing the methanesulfonic acid addition salt of a compound of Formula I: which comprises a crystalline form of the salt of addition of methanesulfonic acid of a compound of Formula I, according to any of claims 25 to 28.
32. 32. The composition according to claim 31, which additionally comprises at least one other form of the acid addition salt methanesulfonic acid of a compound of Formula I, selected from the amorphous form, the crystal-form, the crystal-form, and the crystal form-H1.
33. 33. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 25 to 29, optionally together with a pharmaceutically acceptable carrier.
34. 34. The pharmaceutical composition according to claim 33, which additionally comprises at least one other form of the methanesulfonic acid addition salt of a compound of the Formula I, selected from the amorphous form, the crystal form. a, the crystal-ß form, and the crystal-H1 form.
35. 35. The pharmaceutical composition according to claim 33 or 34, which comprises between 50 milligrams and 800 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of the claims. to 29.
36. 36. The pharmaceutical composition according to any of claims 33 to 35, which is a capsule containing a mixture of dry powder comprising between 50 milligrams and 200 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 25 to 29.
37. 37. The crystalline form I of the methanesulfonic acid addition salt of a compound of the Formula I:
38. 38. The crystalline form according to claim 37, which shows an X-ray diffraction peak at a 2-theta refractive angle of 12.9 ° in the absence of lines at a 2-theta refractive angle below 9 ° and above of 29 °.
39. 39. The crystalline form according to claim 37, which is characterized by X-ray diffraction peaks at a 2-theta refractive angle of 12.9 °, 17.1 °, 20.9 °, 23.9 °, and 24.3 °.
40. 40. The crystalline form of the methanesulfonic acid addition salt of a compound of Formula I according to claim 37, which shows, in the X-ray diffraction diagram, lines at the following refractive angles. Theta: 12.9 °, 14.1 °, 17.1 °, 18.0 °, 18.7 °, 19.1 °, 19.8 °, 20.9 °, 23.9 °, 24.3 °, and 25.2 °.
41. 41. The crystalline form according to any of claims 37 to 40, which is present in a form essentially pure.
42. 42. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: which shows an X-ray diffraction diagram of the type shown in Figure 4, where the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 4 43.
43. A composition containing the methanesulfonic acid addition salt of a compound of Formula I: which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I, according to any of claims 37 to 42.
44. The composition according to claim 43, which additionally comprises at least a different form of the methanesulfonic acid addition salt of a compound of the Formula I, selected from the amorphous form, the crystal-a form, the ß-crystal form, and the H-1 crystal form.
45. 45. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 37 to 42, optionally together with a pharmaceutically acceptable carrier.
46. 46. The pharmaceutical composition according to claim 45, which optionally comprises at least one other form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the crystal-form, the crystal-β form, and the form of crystal-H 1.
47. 47. The pharmaceutical composition according to claim 45 or 46, which comprises between 50 milligrams and 800 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of the claims 37 to 42.
48. 48. The pharmaceutical composition according to any of claims 45 to 47, which is a capsule containing a mixture of dry powder comprising between 50 milligrams and 200 milligrams of a crystalline form of the addition salt. of methanesulfonic acid of a compound of Formula I according to any of claims 37 to 42.
49. 49. The crystalline form K of the methanesulfonic acid addition salt of a compound of Formula I:
50. 50. The crystalline form according to claim 49, which shows, in X-ray diffraction, a peak at a 2-theta refractive angle of 37.9 °.
51. 51. The crystalline form according to claim 49, which is characterized by an X-ray diffraction peak at a 2-theta refractive angle of 21.0 °.
52. 52. The crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to claim 49 or 50, which shows, in an X-ray diffraction diagram, lines at the following refractive angles 2-theta: 12.1 °, 14.1 °, 18.2 °, 18.4 °, 21.0 °, 23.4 °, and 28.4 °.
53. 53. The crystalline form according to any of claims 49 to 52, which is present in an essentially pure form.
54. 54. A crystalline form of the methanesulfonic acid addition salt of a compound of Formula I: which shows an X-ray diffraction diagram of the type shown in Figure 5, where the relative peak intensities of each peak do not deviate by more than 10 percent from the relative peak intensities in the diagram shown in Figure 5.
55. 55. A composition containing the methanesulfonic acid addition salt of a compound of Formula I: which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 49 to 54.
56. The composition according to claim 55, which additionally comprises at least one A different form of the methanesulfonic acid addition salt of a compound of Formula I, selected from the amorphous form, the crystal-form, the crystal-β form, and the HI-crystal form.
57. 57. A pharmaceutical composition, which comprises a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 49 to 54, optionally together with a pharmaceutically acceptable carrier.
58. 58. The pharmaceutic composition according to claim 57, which comprises adding at least one form other than the methanesulfonic acid addition salt of a compound of Formula I, selected from from the form to amorphous, the form of crystal-a, the form of crystal-ß, and the form of crystal-H 1.
59. 59. The pharmaceutical composition according to claim 57 or 58, which comprises between 50 milligrams and 800 milligrams of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of the claims 49 to 54.
60. 60. The pharmaceutical composition according to any of claims 57 to 59, which is a capsule containing a mixture of dry powder comprising between 50 milligrams and 200 milligrams of a crystalline form of the addition salt of Methanesulfonic acid of a compound of Formula I according to any of claims 49 to 54.
61. 61. The capsule according to claim 1 0, 24, 36, 48, or 60, wherein the shell contains gelatin.
62. 62. The capsule according to claim 10, 24, 36, 48, or 60, wherein the cover contains titanium dioxide.
63. 63. The capsule according to claim 1, 24, 36, 48, or 60, wherein the cover contains red iron oxide.
64. 64. The capsule according to claim 1 0, 24, 36, 48, or 60, wherein the ratio of the weight of the capsule filling to the capsule shell is between about 1: 25 and 100: 50
65. 65. The capsule according to claim 10, 24, 36, 48, or 60, wherein the weight ratio of the capsule filling to the capsule shell is between 100: 30 and 100: 40.
66. 66. The pharmaceutical composition according to any of claims 7 to 9, 21 to 23, 33 to 35, 45 to 47, or 57 to 59, which is a tablet comprising 100 milligrams, 400 milligrams, or 800 milligrams of drug substance, together with inactive excipients.
67. 67. The tablet according to claim 66, wherein the inactive excipients are selected from colloidal anhydrous silica, polyvinyl pyrrolidone, magnesium stearate, and microcrystalline cellulose.
68. 68. The use of a crystalline form of the methanesulfonic acid addition salt of a compound of the Formula I according to any of claims 1 or 2, 13 to 16, 25 to 28, 37 to 40, or 49 to 52 , for the preparation of a medicament for the treatment of a disease selected from inoperable metastatic GIST, advanced chronic myeloid leukemia, newly diagnosed chronic myeloid leukemia, pediatric Philadelphia chromosome positive chronic leukemia, acute lymphocytic leukemia (ALL) positive for the Philadelphia chromosome, glioblastoma multiforme, dermatofibrosarcoma protuberans (DFSP), hyper-eosinophilic syndrome (HES), and chronic myelomonocytic leukemia (CMML).
69. 69. A method for the treatment of a disease selected from inoperable metastatic GIST, advanced chronic myeloid leukemia, newly diagnosed chronic myeloid leukemia, pediatric Philadelphia chromosome-positive chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphocytic leukemia (ALL), glioblastoma multiforme, dermatofibrosarcoma protuberans (DFSP), hyper-eosinophilic syndrome (HES), and chronic myelomonocytic leukemia (CMML), in a warm-blooded animal that needs it, which comprises administering to the animal a crystalline form of the acid addition salt Methanesulfonic acid of a compound of Formula I according to any of claims 1 or 2, 13 to 16, 25 to 28, 37 to 40, or 49 to 52, in an amount that is therapeutically effective against the respective disease.
70. 70. The method according to claim 69, wherein a daily dosage of 400 milligrams or 600 milligrams is administered orally to the patient.
71. 71. The method according to claim 70, wherein the total daily dosage is administered once a day with a food and with a large glass of water of approximately 200 milliliters.
72. 72. The method according to claim 69, wherein a daily dosage of 800 milligrams is orally administered to the patient.
73. 73. The method according to claim 72, wherein A total daily dosage is given as a dose of 400 milligrams twice a day along with the food. SUMMARY The invention relates to the F-crystal form, the G-crystal form, the H-crystal form, the l-crystal form, and the K-crystal form of the methanesulfonic acid addition salt. of 4- (4-methyl-piperazin-1-ylmethyl) -N- [4-methyl-3- (4- (pyridin-3-yl) -pyrimidin-2-ylamino) -phenyl] -benzamide, at certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in methods of diagnosis for the therapeutic treatment of warm-blooded animals, especially humans. * * * * *